Guidelines and Reviews:
Polverino E, Goeminne P, McDonnel M, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50:1700629. These guidelines describe appropriate investigation and treatment strategies by posing nine key clinical questions and conducting systematic reviews to answer the questions.
PMID: 28889110
Free Full Text
Imam JS, Duarte AG. Non-CF bronchiectasis: Orphan disease no longer. Respir Med. 2020; 166:105940. A thorough, but concise review of the pathogenesis, epidemiology, clinical features, etiologies, approach to diagnosis, and management of non-CF bronchiectasis.
PMID: 32250872
Free Full Text
Therapeutics:
O’Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998;113:1329-1334. A large multinational trial of patients with idiopathic bronchiectasis found increased exacerbation frequency and a more brisk decrease in FEV1. While noteworthy for its specific findings, this study is widely cited as a reason cystic fibrosis treatment strategies cannot be universally applied to all types of bronchiectasis.
PMID: 9596315
Free Full Text
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-9. A trial of chronic azithromycin treatment in patients with stable non-cystic fibrosis bronchiectasis. Azithromycin was associated with a decreased pulmonary exacerbation rate but increased macrolide resistance.
PMID: 23532241
Free Full Text
